Send to

Choose Destination
Blood Coagul Fibrinolysis. 2015 Dec;26(8):956-8. doi: 10.1097/MBC.0000000000000346.

Factor VII Tokushima: the first case of factor VII Cys22Gly with the development of myocardial infarction in the proband receiving recombinant factor VIIa replacement therapy.

Author information

aDepartment of Hematology bDepartment of Cardiovascular Medicine cDepartment of Gastroenterology, Tokushima Prefectural Central Hospital dDepartment of Medicine and Bioregulatory Sciences eDepartment of Medical Education, Graduated School of Health Biosciences, The University of Tokushima, Tokushima, Japan.


An 81-year-old man was referred to our department because of suspected factor VII (FVII) deficiency. His FVII activity was under 1%, whereas the FVII activity levels of his son and granddaughter were 65 and 109%, respectively. The nucleotide at position 3886 of his FVII gene was homozygous for G. A single T to G substitution results in the replacement of wild-type Cys at residue 22 by Gly. His son was heterozygous for G and T at position 3886, whereas his granddaughter was homozygous for wild-type T. These results suggest that he was homozygous for FVII Cys22Gly. He underwent radiofrequency ablation (RFA) for hepatocellular carcinoma, receiving 20 μg/kg of recombinant FVIIa prior to RFA and 10 μg/kg of recombinant FVIIa twice after RFA. He showed no bleeding tendency; however, a myocardial infarction was diagnosed and percutaneous coronary intervention was performed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center